Dr Meller’s lab at MSM is currently focused in the application of blood transcriptome profiling as a point-of care diagnostic for neurological and neurodegenerative disorders. He has published on molecular mechanisms of acquired resilience in neuronal tissues. He published the first blood RNA-seq study in minority population following stroke, and concussion in a military population. He currently collaborates with researchers at Emory University, Georgia Institute of Technology and the Grady memorial hospital. Dr Meller’s research has been funded by the NIH (NIMHD and NINDS) and AHA. Dr Meller received his D.Phil. in Clinical Pharmacology from the University of Oxford (U.K.) and his BSc from the University of Bristol (U.K.).
Clinical Dx Showcase:
Morehouse School of Medicine
Morehouse School of Medicines mission is to improve the health and well-being of individuals and communities, increase the diversity of the health professional and scientific workforce, and address primary health care through programs in education, research, and service.
Blood Transcriptome Profiling As A Point-Of-Care Diagnostic
Our studies of blood RNA profiling provide highly accurate stroke diagnosis, determines stroke subtype, offer powerful prediction of outcome. Further studies in concussion, and Alzheimer’s disease showing the utility and flexibility of this approach.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.